Latest News and Press Releases
Want to stay updated on the latest news?
-
- Incoming Industry Veteran to Lead Clinical Supply Chain Operations and Architect the Build Out of the Anticipated Commercial Supply Chain NEW YORK, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Actinium...
-
- Incoming specialists to focus on Quality Control and Quality Assurance Aspects of Supply Chain NEW YORK, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM)...
-
- Company is seeking guidance on development plan of Iomab-B for the EU market - Actinium’s small and medium-sized (SME) status and orphan designation results in a 100% reduction in...
-
NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
-
- Orphan designation is expected to provide increased communication and guidance from regulators and 10-year market exclusivity should marketing authorization be obtained - Orphan designation...
-
NEW YORK, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
-
NEW YORK, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
-
NEW YORK, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
-
Webinar to be held at 9:00 AM ET to highlight Actimab-A Phase 2 clinical trial and protocol revisions agreed to by the FDAProtocol revisions agreed to by the FDA include the use of peripheral blast...
-
NEW YORK, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...